Teva and Mylan: War of words continues
This article was originally published in Scrip
Teva and Mylan continue to exchange strongly worded correspondence. On 8 June, Teva's chairman Yitzhak Peterburg and CEO Erez Vigodman issued an open letter to Mylan's executive chairman Robert Coury repeating Teva's $40bn offer for the company and claiming that a combination would add value to both companies. However, they also claimed that Mylan's management was making "grossly incorrect" statements to mislead its stockholders and deprive them of a transparent analysis of Teva's proposal.